Challenges in the development environment arising from drug lags, drug losses, and pharmaceutical supply shortages
First written in FY2024-Q2. 1 of 2 entries say "Restated". Latest entry: FY2024-Q3.
2 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「In Japan's prescription pharmaceutical market, the foundations of pharmaceutical supply are being undermined by drug lag and shortages of generic drugs, while fundamental reform of the drug pricing system is also under discussion. From the perspectives of drug lag and drug loss, the enormous time and cost required to develop pharmaceuticals are also considered challenges.」
Pharmaceutical shortages, drug lag and drug loss, and development timelines and costs continue to be disclosed as challenges in Japan's prescription pharmaceutical market. - FY2024-Q2First statedAnnual report
「In Japan's prescription pharmaceutical market, the foundations of pharmaceutical supply are being undermined by drug lag and shortages of generic drugs, while fundamental reform of the drug pricing system is also under discussion. From the perspectives of drug lag and drug loss, the enormous time and cost required to develop pharmaceuticals are also considered challenges.」
Shortages in Japan's prescription pharmaceutical market, drug lag and drug loss, and development timelines and costs have been comprehensively identified as challenges for the first time.